معرفی
Joseph D. Deak is an Assistant Professor in the Department of Psychiatry at Yale School of Medicine. He is affiliated with the Gelernter Lab and the Janeway Society, and his work bridges clinical psychiatry and genomic research.
- Yale School of Medicine, Department of Psychiatry
- Gelernter Lab
- Janeway Society
Dr. Deak holds a PhD in Clinical Psychology from the University of Missouri (2020) and completed his postdoctoral training at Yale in 2023.
- PhD, Clinical Psychology, University of Missouri, 2020
- Postdoctoral Fellowship, Yale School of Medicine, 2023
- MA, Clinical Psychology, University of Missouri, 2016
- BA, Biology, Saint Louis University, 2010
- BA, Psychology, Saint Louis University, 2010
His research focuses on the genetic underpinnings of substance use disorders (SUDs), psychiatric conditions, and behavioral traits. He utilizes large-scale biobank data, including the Million Veteran Program (MVP) and the Psychiatric Genomics Consortium SUD working group, to conduct genome-wide association studies and causal inference analyses. His work explores comorbidities between SUDs and mental health disorders, genetic risk factors for opioid and alcohol dependence, and the interplay between physical activity, chronic pain, and mental health.
Dr. Deak's recent publications span high-impact journals such as Nature Mental Health, Molecular Psychiatry, and Science. His research trends emphasize the use of genetically-informed methods to unravel causal pathways between substance use, psychiatric disorders, and lifestyle factors. He frequently collaborates with leading researchers like Joel Gelernter, Daniel Levey, and Renato Polimanti.
He has received multiple prestigious awards, including:
- NIH K01 Mentored Research Scientist Development Award (K01DA058807)
- NIH Loan Repayment Program (LRP) Award from NIDA
- Multiple NIAAA T32 Postdoctoral Fellowships through the Translational Alcohol Research Program (TARP)
Dr. Deak is actively involved in mentoring and collaborative research. His work is supported by NIH grants, particularly NIDA, and he contributes to large-scale interdisciplinary research initiatives. He is a key member of research teams leveraging the MVP and PGC-SUD consortia to advance understanding of addiction and mental health. He has no known lab or team named after him but is deeply embedded in the Gelernter Lab’s research ecosystem.